An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2018
At a glance
- Drugs Osimertinib (Primary) ; Osimertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms ODIN-BM
- Sponsors AstraZeneca
- 29 Nov 2018 Planned End Date changed from 25 Nov 2019 to 10 Sep 2019.
- 29 Nov 2018 Planned primary completion date changed from 25 Nov 2019 to 10 Sep 2019.
- 29 Nov 2018 Status changed from not yet recruiting to recruiting.